Company Overview and News
TORONTO, ON / ACCESSWIRE / October 11, 2018 / Galway Metals Inc. (TSX-V: GWM; OTC PINK: GAYMF) (the "Company") is pleased to announce that Debbie G. Laney, P.Eng, has agreed to act as a technical advisor to the Company, assisting in guiding the advancement of Galway's high grade Estrades zinc-gold and Clarence Stream gold properties to optimize their full potential.
GWM KGI KGI.DB.A KGI.DB WDO GAYMF IDMMF WDOFF KL RVRCF IDM
TORONTO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Kirkland Lake Gold Ltd. (“Kirkland Lake Gold” or the “Company”) (TSX:KL) (NYSE:KL) (ASX:KLA) today announced record quarterly gold production of 180,155 ounces for the third quarter of 2018 (“Q3 2018”). Production in Q3 2018 exceeded target levels for the quarter driven by record quarterly production from Fosterville of 90,618 ounces as well as from the Company’s Canadian operations, with Macassa, Holt and Taylor collectively producing 89,537 ounces.
KGI KGI.DB.A KGI.DB KL
TORONTO, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Kirkland Lake Gold Ltd. (“Kirkland Lake Gold” or the “Company”) (TSX:KL) (NYSE:KL) (ASX:KLA) today announced that the Company will release its financial and operating results for the third quarter and first nine months of 2018 after the market close on Tuesday, October 30, 2018. The Company will then host a conference call to review the results the next morning (Wednesday, October 31, 2018) at 8:00 am ET.
KGI KGI.DB.A KGI.DB KL
VANCOUVER, British Columbia, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Strongbow Exploration Inc. (TSX-V: SBW) (“Strongbow” or the “Company”) announces that Mr. John Burzynski will be stepping down from his role as Director effective today. The Company would like to thank Mr. Burzynski for his tremendous efforts and support in advancing Strongbow and the South Crofty project. John will join Strongbow’s Technical Advisory Committee in a continuing role with the Company.
ASOLF KGI SBLRF KGI.DB.A KGI.DB SAE AOT SBWFF KL
De Grey Mining Limited (ASX:DEG) shareholders have backed the company’s acquisition of Chinese company Indee Gold Pty Ltd giving it the Western Australian company the all-clear to take stake in its flagship Pilbara Gold Project to 100%.
DEG ASX ASXFF KGI ASXFY KGI.DB.A DRMGF DGO KGI.DB KL
Monash University, Kirkland Lake Gold and 2018 Prospect Awards nominee Deepcore Drilling are providing invaluable mine site exposure for university students.
KGI KGI.DB.A KGI.DB KL
Australian Mining has released the list of finalists for the 2018 Prospect Awards, representing a variety of individuals and companies, from small startups to major mining companies.
MNDJF KGI KGI.DB.A KGI.DB RRL MSV RGRNF KL ROK
2018-10-01 seekingalpha - 7
Science and art, or if you prefer skill and luck, are both needed for consistent success in short-term trading to long-term investing. Some deny this and say it's all math, claiming that markets always represent fair value. If so, high-frequency trading algo-bot scalpers will always win, meaning people can never outsmart to beat the market as all opportunities and risks are fully discounted into prices.
STZ.B TWX MEAOF BTR AMZN AABA LVNSF FQM NDM MISVF HVBTF GDX AXXDF STZ TWC PRU SLV BABA ATUSF AAUKF VZ BALMF BB FB DB KGI.DB NFLX GOOG GLD TLRY ALS WEED NAK PMNXF AAPL FQVLF PRU ADV BLKCF DIS KL GDXJ EGO FM KGI MSV KGI.DB.A AAL CGC NDMWF ELD BAR NGLOY
De Grey Mining Ltd (ASX:DEG) will begin testing what could be more conglomerate gold nuggets from its Pilbara Gold Project 80 kilometres southwest of Port Hedland.
DEG PIO KGI NSRPF NEM KGI.DB.A KGI.DB NVO PIONF KL
NEW YORK, Sept 25 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX fell 47.82 points, or 0.3 percent, to 16,159.50. * Leading the index were Ivanhoe Mines Ltd, up 7.0 percent, Aurora Cannabis Inc, up 4.1 percent, and Kirkland Lake Gold Ltd , higher by 4 percent. * Lagging shares were Martinrea International Inc, down 4.9 percent, Magna International Inc, down 4.7 percent, and AltaGas Ltd, lower by 3.
MRETF KGI KGI.DB.A ACBFF KGI.DB IVN IVPAF ACB ATGFF MGA APH MRE MG BTE APHQF ALA KL
2018-09-25 seekingalpha - 1
Another CEO is having a shot at fixing New Gold. Unfortunately, things have gone from bad to worse since the last iteration on this theme. Welcome to this week's
OCANF CAT IVN LIACF TMMFF NGD NSU BTR AMGGF IAG IPMLF ABX III NGD GPL OKSWF EQXGF RGLD ATUSF MNIKF AMLM OSKGF VTT RGL HRT VDTAF HRTFF BDREF CGOOF KGI.DB NGDAF CG VITFF TREVF AGI CAGDF OR RIC CSFFF CS KL CORVF EGO RIC ABX KOR KGI KGI.DB.A AGI BDR VIT IVPAF TMR ELD
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...